Investment Projects
Higher Capital Expenditures for Future Growth
We are intensifying our investment in capacity expansion until 2030, our aim being to meet strong demand from our customers. Capital expenditures in our chemical divisions focus mainly on specialty applications, where we are doubling annual investment spending to more than 400 million euros. We are scaling up expansion of our biotech activities by investing more than 80 million euros a year. Our polysilicon business is focusing on semiconductor applications, where we plan to invest some 100 million euros annually.
Investment Projects
1
Wacker Silicones
- Facilities for specialty silicones
- CAPEX > €100 million
- Site Charleston
- Completion date 2025
- Products Heat-curing solid silicone rubber, silicone sealants
2
Wacker Silicones
- Facilities for specialty silicones
- CAPEX > €100 million
- Site Nünchritz
- Completion date 2023 – 2024
- Products Hybrid polymers, silanes, liquid resins
3
Wacker Silicones
- Facilities for specialty silicones
- CAPEX < €100 million
- Site Burghausen
- Completion date 2023 - 2024
- Products Silicone resins, silicone sealants, hydrogen chloride
3
Wacker Polysilicon
- Capacity expansion for electronic-grade silicon
- CAPEX > €100 million
- Site Burghausen
- Completion date 2023 - 2026
- Products Polysilicon for semiconductor wafers; trichlorosilane for the production of polysilicon; specialty silanes
4
Wacker Silicones
- Facilities for specialty silicones
- CAPEX < €100 million
- Site Panagarh
- Completion date 2023
- Products High-consistency and liquid silicone rubbers for applications in the fields of electromobility and medical technology
5
Wacker Polymers
- Facilities for dispersible polymer powders; infrastructure
- CAPEX > €100 million
- Site Nanjing
- Completion date 2023
- Products Dispersible polymer powders for construction applications
6
Wacker Biosolutions
- Biotechnology research center
- CAPEX < €100 million
- Site Munich
- Completion date 2024
- Products Development of production methods for biopharmaceuticals and the fermentative production of ingredients for nutritional supplements
7
Wacker Biosolutions
- Competence center for mRNA actives
- CAPEX > €100 million
- Site Halle
- Completion date 2024
- Products mRNA actives for vaccines and therapeutic agents
